“Cytomegalovirus (CMV) Infection Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cytomegalovirus (CMV) Infection Market.
The Cytomegalovirus (CMV) Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Cytomegalovirus (CMV) Infection Pipeline Report:
Companies across the globe are diligently working toward developing novel Cytomegalovirus (CMV) Infection treatment therapies with a considerable amount of success over the years.
Cytomegalovirus (CMV) Infection companies working in the treatment market are antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others, are developing therapies for the Cytomegalovirus (CMV) Infection treatment
Emerging Cytomegalovirus (CMV) Infection therapies in the different phases of clinical trials are- Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others are expected to have a significant impact on the Cytomegalovirus (CMV) Infection market in the coming years.
In May 2025, Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharma company specializing in rare and serious conditions and a leader in specialty plasma-derived therapies, has announced the initiation of a new post-marketing research initiative. This program aims to generate important data highlighting the benefits of CYTOGAM®—Kamada’s Cytomegalovirus Immune Globulin—for managing cytomegalovirus (CMV) in patients undergoing solid organ transplantation.
In March 2025, ACTG, an international clinical trials network dedicated to HIV and infectious diseases, has unveiled encouraging results from a study investigating the impact of treating asymptomatic cytomegalovirus (CMV) in individuals living with HIV. The findings suggest that CMV suppression may enhance immune function and overall physical health. Shared at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, the results come from study A5383 and were presented as an oral abstract titled, “Asymptomatic CMV Suppression with Letermovir Improves Immunologic and Functional Aging-related Outcomes in Treated HIV.
In January 2025, Fortress Biotech, Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Helocyte, Inc., announced that the first patient has been dosed in a multicenter, randomized, placebo-controlled Phase 2 clinical trial. The study aims to assess the effectiveness of Triplex, a cytomegalovirus (CMV) vaccine, when given to human leukocyte antigen (HLA)-matched related stem cell donors to reduce CMV occurrences in patients undergoing hematopoietic stem cell transplantation (HSCT).
In February 2024, A novel mRNA vaccine currently undergoing phase 3 clinical trials demonstrated superior efficacy in stimulating the immune system to combat Cytomegalovirus (CMV) Infection. This experimental mRNA vaccine targeting human cytomegalovirus (CMV), a prevalent virus with potential prenatal transmission, has elicited highly encouraging immune responses compared to other CMV vaccine candidates, as per research conducted by investigators from Weill Cornell Medicine.
Cytomegalovirus (CMV) Infection Overview
Cytomegalovirus (CMV) Infection is a common viral infection caused by the cytomegalovirus, a type of herpes virus. CMV is widespread and can infect people of all ages. In healthy individuals with intact immune systems, CMV infection often causes mild or no symptoms and may go unnoticed. However, in individuals with weakened immune systems, such as those with HIV/AIDS, organ transplant recipients, or infants infected in utero, CMV infection can lead to more severe complications.
Get a Free Sample PDF Report to know more about Cytomegalovirus (CMV) Infection Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight
Emerging Cytomegalovirus (CMV) Infection Drugs Under Different Phases of Clinical Development Include:
Research programme: antiviral therapeutics TSRL
SYN002: Synklino
Posoleucel: AlloVir
mRNA-1647: Moderna
CMV TCR T cell therapy: China Immunotech
NPC-21: Nobelpharma
HB-101: Hookipa Biotech GmbH
Cytomegalovirus immune globulin: Biotest
VBI-1501A: VBI Vaccines
LTV 20: Lion TCR
Maribavir: Shire
V160: Merck Sharp & Dohme
Maribavir: Takeda
Valganciclovir: CSL Behring
Brincidofovir: Chimerix
Everolimus: Novartis
HB-101 vaccine: Hookipa Biotech GmbH
Cytomegalovirus (CMV) Infection Route of Administration
Cytomegalovirus (CMV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intranasal
Intrathecal
Intravenous
Oral
Oral/Intravenous
Parenteral
Subcutaneous
Subcutaneous/Intramuscular
Transdermal
Cytomegalovirus (CMV) Infection Molecule Type
Cytomegalovirus (CMV) Infection Products have been categorized under various Molecule types, such as
Antisense oligonucleotide
Gene therapy
Hormones
Neuropeptides
Oligonucleotides
Small Molecule
Triglyceride
Cytomegalovirus (CMV) Infection Pipeline Therapeutics Assessment
Cytomegalovirus (CMV) Infection Assessment by Product Type
Cytomegalovirus (CMV) Infection By Stage and Product Type
Cytomegalovirus (CMV) Infection Assessment by Route of Administration
Cytomegalovirus (CMV) Infection By Stage and Route of Administration
Cytomegalovirus (CMV) Infection Assessment by Molecule Type
Cytomegalovirus (CMV) Infection by Stage and Molecule Type
DelveInsight’s Cytomegalovirus (CMV) Infection Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Cytomegalovirus (CMV) Infection product details are provided in the report. Download the Cytomegalovirus (CMV) Infection pipeline report to learn more about the emerging Cytomegalovirus (CMV) Infection therapies
Some of the key companies in the Cytomegalovirus (CMV) Infection Therapeutics Market include:
Key companies developing therapies for Cytomegalovirus (CMV) Infection are – Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, and others.
Cytomegalovirus (CMV) Infection Pipeline Analysis:
The Cytomegalovirus (CMV) Infection pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Cytomegalovirus (CMV) Infection with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytomegalovirus (CMV) Infection Treatment.
Cytomegalovirus (CMV) Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cytomegalovirus (CMV) Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytomegalovirus (CMV) Infection market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cytomegalovirus (CMV) Infection drugs and therapies
Cytomegalovirus (CMV) Infection Pipeline Market Drivers
Increasing Prevalence of Cytomegalovirus (CMV) Infection, increase in Research and developmental Activities are some of the important factors that are fueling the Cytomegalovirus (CMV) Infection Market.
Cytomegalovirus (CMV) Infection Pipeline Market Barriers
However, high costs associated with the treatment, lack of healthcare infrastructures and other factors are creating obstacles in the Cytomegalovirus (CMV) Infection Market growth.
Scope of Cytomegalovirus (CMV) Infection Pipeline Drug Insight
Coverage: Global
Key Cytomegalovirus (CMV) Infection Companies: antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others
Key Cytomegalovirus (CMV) Infection Therapies: Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others
Cytomegalovirus (CMV) Infection Therapeutic Assessment: Cytomegalovirus (CMV) Infection current marketed and Cytomegalovirus (CMV) Infection emerging therapies
Cytomegalovirus (CMV) Infection Market Dynamics: Cytomegalovirus (CMV) Infection market drivers and Cytomegalovirus (CMV) Infection market barriers
Request for Sample PDF Report for Cytomegalovirus (CMV) Infection Pipeline Assessment and clinical trials
Table of Contents
1. Cytomegalovirus (CMV) Infection Report Introduction
2. Cytomegalovirus (CMV) Infection Executive Summary
3. Cytomegalovirus (CMV) Infection Overview
4. Cytomegalovirus (CMV) Infection- Analytical Perspective In-depth Commercial Assessment
5. Cytomegalovirus (CMV) Infection Pipeline Therapeutics
6. Cytomegalovirus (CMV) Infection Late Stage Products (Phase II/III)
7. Cytomegalovirus (CMV) Infection Mid Stage Products (Phase II)
8. Cytomegalovirus (CMV) Infection Early Stage Products (Phase I)
9. Cytomegalovirus (CMV) Infection Preclinical Stage Products
10. Cytomegalovirus (CMV) Infection Therapeutics Assessment
11. Cytomegalovirus (CMV) Infection Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cytomegalovirus (CMV) Infection Key Companies
14. Cytomegalovirus (CMV) Infection Key Products
15. Cytomegalovirus (CMV) Infection Unmet Needs
16 . Cytomegalovirus (CMV) Infection Market Drivers and Barriers
17. Cytomegalovirus (CMV) Infection Future Perspectives and Conclusion
18. Cytomegalovirus (CMV) Infection Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
